Glenmede Trust’s Kite Pharma, Inc. KITE Stock Holding History

Glenmede Trust’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21	Closed	-$1K	–	2717
2016 Q3	$1K	Buy	+21	New	+$1.17K	﹤0.01%	2539
2016 Q1	–	Sell	-55	Closed	-$3K	–	2792
2015 Q4	$3K	Hold	55	–	–	﹤0.01%	2417
2015 Q3	$3K	Hold	55	–	–	﹤0.01%	2454
2015 Q2	$3K	Sell	55 -7	-11%	-$399	﹤0.01%	2390
2015 Q1	$3K	Buy	62 +7	+13%	+$469	﹤0.01%	2339
2014 Q4	$3K	Buy	+55	New	+$2.32K	﹤0.01%	2391

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Glenmede Trust's KITE Position: Q4 2016 in Review

Glenmede Trust sold out of Kite Pharma, Inc. (KITE) in Q4 2016, closing a stake of 21 shares — an estimated $1K sold.

Glenmede Trust first reported a position in KITE in Q4 2014 and held it in 6 quarters. The position peaked at $3K in Q4 2015. 184 funds tracked by Wall St. Rank hold KITE as of Q4 2016.

Glenmede Trust reported no remaining Kite Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
Glenmede Trust sold 21 Kite Pharma, Inc. shares in Q4 2016, an estimated $1K.
Glenmede Trust first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 6 quarters.
Glenmede Trust's Kite Pharma, Inc. position peaked at $3K in Q4 2015.
184 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2016.

Based on Glenmede Trust's 13F filing for Q4 2016, filed 14 Feb 2017.